首页> 美国卫生研究院文献>Springer Open Choice >Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates
【2h】

Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates

机译:定量评估原发性胶质母细胞瘤中基因内受体酪氨酸激酶的缺失:其患病率和分子相关性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Intragenic deletion is the most common form of activating mutation among receptor tyrosine kinases (RTK) in glioblastoma. However, these events are not detected by conventional DNA sequencing methods commonly utilized for tumor genotyping. To comprehensively assess the frequency, distribution, and expression levels of common RTK deletion mutants in glioblastoma, we analyzed RNA from a set of 192 glioblastoma samples from The Cancer Genome Atlas for the expression of EGFRvIII, EGFRvII, EGFRvV (carboxyl-terminal deletion), and PDGFRAΔ8,9. These mutations were detected in 24, 1.6, 4.7, and 1.6 % of cases, respectively. Overall, 29 % (55/189) of glioblastomas expressed at least one RTK intragenic deletion transcript in this panel. For EGFRvIII, samples were analyzed by both quantitative real-time PCR (QRT-PCR) and single mRNA molecule counting on the Nanostring nCounter platform. Nanostring proved to be highly sensitive, specific, and linear, with sensitivity comparable or exceeding that of RNA seq. We evaluated the prognostic significance and molecular correlates of RTK rearrangements. EGFRvIII was only detectable in tumors with focal amplification of the gene. Moreover, we found that EGFRvIII expression was not prognostic of poor outcome and that neither recurrent copy number alterations nor global changes in gene expression differentiate EGFRvIII-positive tumors from tumors with amplification of wild-type EGFR. The wide range of expression of mutant alleles and co-expression of multiple EGFR variants suggests that quantitative RNA-based clinical assays will be important for assessing the relative expression of intragenic deletions as therapeutic targets and/or candidate biomarkers. To this end, we demonstrate the performance of the Nanostring assay in RNA derived from routinely collected formalin-fixed paraffin-embedded tissue.Electronic supplementary materialThe online version of this article (doi:10.1007/s00401-013-1217-3) contains supplementary material, which is available to authorized users.
机译:基因内缺失是胶质母细胞瘤中受体酪氨酸激酶(RTK)中激活突变的最常见形式。然而,这些事件不能通过通常用于肿瘤基因分型的常规DNA测序方法检测到。为了全面评估胶质母细胞瘤中常见RTK缺失突变体的频率,分布和表达水平,我们分析了来自癌症基因组图谱的192个胶质母细胞瘤样本中的RNA,以表达EGFRvIII,EGFRvII,EGFRvV(羧基末端缺失),和PDGFRAΔ8,9。这些突变分别在24%,1.6%,4.7%和1.6%的病例中被检测到。总体而言,该小组中有29%(55/189)的胶质母细胞瘤表达了至少一种RTK基因内缺失转录本。对于EGFRvIII,通过定量实时PCR(QRT-PCR)和Nanostring nCounter平台上的单个mRNA分子计数来分析样品。纳米串被证明是高度敏感的,特异性的和线性的,其敏感性可与RNA seq相媲美或超过RNA seq。我们评估了RTK重排的预后意义和分子相关性。 EGFRvIII仅在具有基因局部扩增的肿瘤中可检测到。此外,我们发现EGFRvIII表达不能预示不良的预后,并且既不重复表达拷贝数变化也不基因表达的整体变化将EGFRvIII阳性肿瘤与野生型EGFR扩增的肿瘤区分开。突变等位基因的广泛表达和多种EGFR变体的共表达表明,基于定量RNA的临床测定对于评估作为治疗靶标和/或候选生物标记的基因内缺失的相对表达将是重要的。为此,我们证明了纳米串测定法在常规收集的福尔马林固定石蜡包埋的组织中提取的RNA中的性能。电子补充材料本文的在线版本(doi:10.1007 / s00401-013-1217-3)包含补充材料,可供授权用户使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号